Working… Menu
Trial record 6 of 62 for:    Baricitinib

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD6)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03559270
Recruitment Status : Enrolling by invitation
First Posted : June 18, 2018
Last Update Posted : November 22, 2019
Incyte Corporation
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : November 25, 2021
Estimated Study Completion Date : December 27, 2021